Today: 20 May 2026
Palantir stock slips even as Daiwa turns bullish, investors brace for jobs data
10 February 2026
1 min read

Palantir stock slips even as Daiwa turns bullish, investors brace for jobs data

New York, Feb 10, 2026, 16:13 EST — After-hours

  • Palantir dropped 2.3% on Tuesday, trailing a mixed U.S. session.
  • Daiwa bumped Palantir up to “buy,” slapping a $180 price target on the stock.
  • Wednesday’s U.S. jobs report has investors on alert, hunting for the next move in high-growth tech.

Palantir Technologies dropped 2.3% to $139.63 in Tuesday’s session, shrugging off an upgrade to “buy” from Daiwa Securities Group.

This shift is notable. Palantir now acts as a high-beta stand-in for Wall Street’s mood on AI software demand—a role that’s seen plenty of volatility this month. Investors are getting jittery, wondering just how quickly all that spending will show up on the bottom line.

U.S. equities closed with uneven results on Tuesday as retail sales fell short of forecasts, and investors kept their positions tight, waiting for the postponed jobs data set for Wednesday, according to Reuters. “Nobody wants to get too far above their risk budget,” said Mark Luschini, chief investment strategist at Janney Montgomery Scott. Reuters

Daiwa bumped its price target to $180, projecting where the stock might land in the coming year, a MarketBeat note showed.

Palantir shares swung from $137.78 to $146.24 on Tuesday, underscoring the volatility that continues to grip the software group.

Beyond the figures, the company is facing fresh questions from within its own ranks about its ties to U.S. immigration enforcement. WIRED says CEO Alex Karp addressed the issue in a video sent to staff—it ran close to an hour—fielding ICE-related concerns and promising NDAs for anyone wanting deeper disclosure. “We’re behind the curve internally,” he acknowledged in the recording, according to WIRED. WIRED

Questions about political backlash and increased scrutiny haven’t been far from investors’ minds when it comes to Palantir’s government contracts—an issue CEO Alex Karp has batted down in recent remarks.

Valuation presents another, less obvious risk. A jolt in macro data can swiftly knock down stocks priced for big growth—particularly while questions swirl about just how sturdy demand really is for “AI” software seats and related tools.

Next up: traders are eyeing Wednesday’s U.S. nonfarm payrolls data, which has the potential to shake up rate-cut expectations and, by extension, demand for high-multiple software stocks such as Palantir.

Stock Market Today

  • Stock Market Today May 20: Nasdaq Rises 1.5% on Renewed Risk Appetite
    May 20, 2026, 5:43 PM EDT. The S&P 500 gained 1.08% to 7,432.97, Nasdaq rose 1.54% to 26,270.36, and Dow advanced 1.31% to 50,009.34 amid falling oil prices and easing Treasury yields. AI hardware stocks like AMD and Super Micro Computer led gains, with Nvidia up 1.3% before its earnings report. Software names Salesforce and CrowdStrike also recovered. Hasbro declined nearly 9% despite beating earnings forecasts due to cautious guidance. Investor optimism reflects hopes for an end to the U.S.-Iran conflict, lowering West Texas Intermediate crude by 5% to $99 a barrel. Nvidia's earnings beat was met with muted reaction as investors awaited stronger sales forecasts. The Motley Fool highlighted other top stock picks, noting Nvidia and Netflix's historic outperformance over the S&P 500.

Latest articles

MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

20 May 2026
MicroAlgo shares surged 39.95% to $5.36 after the company announced a quantum image-processing algorithm, with volume reaching 9.74 million shares versus a 447,270 average. The stock hit $6.87 intraday before slipping to $5.22 after hours. No customer deals, revenue targets, or product launch dates were disclosed. Market cap stood near $66.7 million at the close.
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

20 May 2026
Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
FuelCell Energy surges as AI-fueled rally hits again, analysts wary

FuelCell Energy surges as AI-fueled rally hits again, analysts wary

20 May 2026
FuelCell Energy shares surged 16.5% to $20.22 Wednesday, rebounding after a two-day selloff. The move tracked a 1.5% gain in the Nasdaq Composite and renewed interest in companies supplying power to AI data centers. FuelCell reported a $26.1 million quarterly loss and a declining backlog, despite higher revenue and new data-center proposals. Peers traded mixed, with Bloom Energy up and Plug Power down.
Eli Lilly stock price dips as $2.4 billion Orna deal and China pact grab attention
Previous Story

Eli Lilly stock price dips as $2.4 billion Orna deal and China pact grab attention

Abpro Holdings stock slides in premarket after Goldman stake filing sparks wild ABP swings
Next Story

Abpro Holdings stock slides in premarket after Goldman stake filing sparks wild ABP swings

Go toTop